来自官方财务报表的收入、利润与现金流历史。
West Pharmaceutical Services, Inc. 在美洲、欧洲、中东、非洲和亚太地区设计、制造和销售注射药物和保健产品的密封和输送系统。它分为两个部门：专有产品部门和合同制造产品部门。专有产品部门为可注射包装系统提供塞子和密封件；注射器和药筒组件，包括满足注射药物应用需求的定制解决方案，以及通过先进的重构、混合和转移技术增强药物安全输送的管理系统；以及薄膜、涂层、清洗、视觉检查和灭菌工艺和服务，以提高包装产品的质量。该部门还提供小瓶、注射器和药筒形式的药物密封解决方案；和自注射装置；以及一系列综合解决方案，包括分析实验室服务、预先批准初级包装支持和工程开发、监管专业知识和售后技术支持。该部门为生物制品、仿制药和制药公司提供服务。合同制造产品部门涉及手术、诊断、眼科、注射和其他药物输送系统以及消费品中使用的设备的设计、制造和自动化组装。该部门主要服务于制药、诊断和医疗器械公司。它通过其销售队伍和分销网络、合同销售代理和区域分销商销售和分销其产品。 West Pharmaceutical Services, Inc. 成立于 1923 年，总部位于宾夕法尼亚州埃克斯顿。
机器翻译
| 利润表 | TTM → 2026-09-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $3.4B | $3.1B | $2.9B | $3.0B | $2.9B | $2.8B | $2.1B | $1.8B | $1.7B | $1.6B | $1.5B | $1.4B | $1.4B | $1.4B | $1.3B | $1.2B | $1.1B | $1.1B | $1.1B | $1.0B | $913M |
| 毛利 | $1.3B | $1.1B | $1.0B | $1.1B | $1.1B | $1.2B | $768M | $609M | $546M | $513M | $501M | $456M | $448M | $435M | $388M | $339M | $318M | $304M | $303M | $292M | $262M |
| 毛利率% | 37.6% | 35.9% | 34.6% | 38.4% | 39.5% | 41.4% | 35.8% | 33.0% | 31.8% | 32.1% | 33.2% | 32.6% | 31.5% | 31.8% | 30.6% | 28.4% | 28.7% | 28.8% | 28.8% | 28.6% | 28.7% |
| 营业利润（EBIT） | $780M | $617M | $595M | $711M | $764M | $759M | $419M | $297M | $255M | $229M | $197M | $129M | $182M | $162M | $136M | $116M | $106M | $106M | $125M | $113M | $106M |
| 营业利润率% | 23.0% | 20.1% | 20.6% | 24.1% | 26.5% | 26.8% | 19.5% | 16.1% | 14.8% | 14.3% | 13.0% | 9.2% | 12.8% | 11.9% | 10.8% | 9.7% | 9.6% | 10.0% | 11.8% | 11.1% | 11.6% |
| 净利 | $639M | $494M | $493M | $593M | $586M | $662M | $346M | $242M | $207M | $151M | $144M | $96M | $127M | $112M | $81M | $76M | $65M | $73M | $86M | $71M | $67M |
| 净利润率 % | 18.8% | 16.1% | 17.0% | 20.1% | 20.3% | 23.4% | 16.1% | 13.1% | 12.0% | 9.4% | 9.5% | 6.8% | 8.9% | 8.2% | 6.4% | 6.3% | 5.9% | 6.9% | 8.2% | 6.9% | 7.3% |
| EBITDA | — | $724M | $744M | $844M | $808M | $880M | $519M | $403M | $353M | $326M | $288M | $218M | $272M | $248M | $200M | $183M | $161M | $166M | $186M | $158M | $150M |
| 每股收益（EPS） | $8.92 | $6.79 | $6.69 | $7.88 | $7.73 | $8.67 | $4.57 | $3.21 | $2.74 | $1.99 | $1.91 | $1.30 | $1.75 | $1.57 | $1.12 | $1.02 | $0.89 | $1.00 | $1.19 | $0.98 | $1.00 |
| 已发行股数 (M) | — | 73M | 74M | 75M | 76M | 76M | 76M | 75M | 75M | 76M | 75M | 74M | 73M | 71M | 72M | 74M | 73M | 73M | 72M | 72M | 67M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 WST 交互式查看器。 /companies/us/WST
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms